- Medical - Diagnostics & Research
- Healthcare
-
7.56
EPS
-
19.95
P/E
-
16.8B
MARKET CAP
-
1.94%
DIV YIELD
Company Overview
500 PLAZA DRIVE,SECAUCUS NJ 07094,9735202700
CEO
Mr. James E. Davis
Employess
50000
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Website
https://www.questdiagnostics.com
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Next Earnings Date
Oct. 22, 2024
Ex Dividends date
Jul. 22, 2024
Dividend Date
July 8, 2024
YTD Performance
7.07%
Fiscal Year End
12-31
IPO Date
1996-12-17
Growth Rates
(avg. rate of change) | 10 years | 5 years | 3 years | 1 year |
---|---|---|---|---|
Sales/Revenue | 2.62% | 4.20% | -0.66% | -6.38% |
EPS | 3.12% | 7.01% | -10.76% | -6.53% |
Equity | 4.80% | 3.87% | -2.28% | 7.03% |
Cash | 13.88% | 38.42% | -16.01% | 117.78% |
Return On Capital (ROIC) | 10.71% | 11.67% | 12.21% | 9.44% |
Debt
year (millions) | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Short Term Debt | 456 | 155 | 153 | 143 | 949 |
Long Term Debt | 4,410 | 4,470 | 4,500 | 4,510 | 4,380 |
LT Finance Leases | 503 | 642 | 645 | 640 | 558 |
Shares Outstanding | 112 | 116 | 125 | 134 | 134 |
Market Cap | 15,400 | 18,100 | 21,600 | 16,000 | 14,300 |
Price
News
Quest Diagnostics (DGX) Gains From Innovation, Customer Wins
1 monthA key driver in Brain Health growth is Quest Diagnostics' (DGX) Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF Tests for diagnosing and monitoring.
zacks.comShould Quest Diagnostics (DGX) be in Your Portfolio Now?
1 monthQuest Diagnostics' (DGX) robust base business performance instills optimism for long-term growth.
zacks.comPregnant Women Undertested for STIs, Finds Quest Diagnostics Health Trends® Study of Over 4 Million Pregnancies
1 monthOne in three women who tested positive for chlamydia or gonorrhea while pregnant were not retested before giving birth, despite potential to transmit infections to newborns SECAUCUS, N.J. , Aug. 12, 2024 /PRNewswire/ -- A new study by researchers from Quest Diagnostics (NYSE: DGX) and the University of Alabama suggests adherence to guideline-based laboratory testing and treatment of pregnant women for two of the most prevalent sexually transmitted infections (STIs) is suboptimal in the United States, with potentially dire effects on maternal and newborn health.
prnewswire.comQuest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?
1 monthQuest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
zacks.comQuest Diagnostics Named a "Best Place to Work for Disability Inclusion" for Seventh Straight Year
2 monthsQuest achieves top score of 100 on 2024 Disability Equality Index® Best Places to Work for Disability Inclusion SECAUCUS, N.J. , Aug. 1, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced it has been named to the 2024 Disability Equality Index® Best Places to Work for Disability Inclusion by Disability: IN and the American Association of People with Disabilities (AAPD).
prnewswire.com4 Stocks to Watch From a Challenging Outpatient Home Health Industry
2 monthsDespite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, EHC and ADUS are well-poised to gain.
zacks.comDGX vs. PNTG: Which Stock Is the Better Value Option?
2 monthsInvestors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Quest Diagnostics (DGX) or The Pennant Group, Inc. (PNTG). But which of these two stocks is more attractive to value investors?
zacks.comAre Investors Undervaluing Quest Diagnostics (DGX) Right Now?
2 monthsHere at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.comHaystack Oncology and Université de Montréal's affiliated hospital research centre, the CRCHUM, to Deploy Haystack MRD™ Technology in Research Study for Metastatic Colorectal Cancer
2 monthsBALTIMORE, Md. and MONTREAL , July 29, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, announced today a research collaboration with Dr. Simon Turcotte, hepatopancreatobiliary surgeon and scientist at Université de Montréal's affiliated hospital research centre, the CRCHUM, to utilize Haystack Oncology's personalized MRD technology (Haystack MRD™) to evaluate treatment effectiveness in patients with metastatic colorectal cancer (mCRC) with metastases confined to the liver.
prnewswire.comQuest Diagnostics: Beat Down After Beating Q2 Estimates
2 monthsQuest Diagnostics: Beat Down After Beating Q2 Estimates
seekingalpha.comBD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases
2 monthsCollaboration on Flow Cytometry-Based Companion Diagnostics to Advance Personalized Health Care FRANKLIN LAKES, N.J. and SECAUCUS, N.J.
prnewswire.comQuest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal
2 monthsQuest Diagnostics' (DGX) subsidiary, Haystack Oncology, partners on the use of its MRD technology.
zacks.com